Needham analyst Gil Blum raised the firm’s price target on Sarepta to $160 from $158 and keeps a Buy rating on the shares. The company’s 2023 product revenue guidance topped his expectations, but the key value driver for the stock is its May 29 PDUFA date for its gene therapy, SRP-9001, the analyst tells investors in a research note. Blum adds that he remains bullish on SRP-9001 approval and launch by mid-2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Sarepta expects to exceed FY22 guidance for net product revenues
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
- Catalent, Sarepta expand commercial collaboration with deal for DMD candidate
- Nippon Shinyaku upgraded to Hold from Underperform at Jefferies
- Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
